Bicara Therapeutics (NASDAQ:BCAX) COO Sells $715,176.00 in Stock

Key Points

• Ryan Cohlhepp, COO of Bicara Therapeutics, sold 39,600 shares at an average price of $18.06 for a total of $715,176, significantly decreasing his stake by 16.15%.
• Bicara Therapeutics stock recently traded down by 0.9%, closing at $18.00, with a market capitalization of approximately $982.98 million.
• The company's latest earnings report showed a loss of ($0.50) EPS, which was better than analysts' expectations of ($0.54).

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 39,600 shares of the company's stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $18.06, for a total value of $715,176.00. Following the sale, the chief operating officer owned 205,541 shares in the company, valued at approximately $3,712,070.46. This represents a 16.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ryan Cohlhepp also recently made the following trade(s):

• On Tuesday, October 7th, Ryan Cohlhepp sold 10,900 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $196,854.00.

Bicara Therapeutics Trading Down 0.9%

Shares of Bicara Therapeutics stock traded down $0.17 on Wednesday, reaching $18.00. 514,631 shares of the company were exchanged, compared to its average volume of 579,256. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $28.09. The company has a market capitalization of $982.98 million and a price-to-earnings ratio of -5.68. The company has a 50-day moving average of $12.09 and a 200 day moving average of $11.76.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.04. Analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

A number of institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth $25,000. CWM LLC bought a new stake in shares of Bicara Therapeutics during the 1st quarter worth $29,000. Legal & General Group Plc lifted its position in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock worth $32,000 after buying an additional 1,474 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after buying an additional 3,866 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. Piper Sandler assumed coverage on Bicara Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright decreased their target price on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.